Coronavirus Update:What patients and families need to know
The Children's National Research Institute
Children's National Start-Ups
Adipomics is creating the first non-invasive “anticipatory medicine” diagnostic that detects risk for obesity-related diseases prior to the onset of overt clinical signs or symptoms. Personalized exosome-based therapies will follow since we can isolate adipocyte-derived exosomes and change their content.
AlgometRx, Inc. is a medical device start-up that objectively measures pain and drug effect. The company was spun out from Children's National in 2015 by Julia Finkel, M.D., a pediatric anesthesiologist. The device determines pain type and intensity, as well as the suitability of an intervention. The intervention is then fine-tuned as needed to optimize an individual’s pain management. It is currently the only web-enabled mobile device which objectively measures pain and monitors safe use of an opioid or analgesic in patients 30 weeks post conceptual through geriatrics.
AlgometRx is one of eight companies selected out of 250+ by the FDA for Breakthrough Device Status/Early Access pathway for its Rapid Drug Test targeting Opioid Use Disorder. The company is currently in the Research Prototype phase with ongoing clinical trials being conducted at Children's National. Commercial approval of the Rapid Drug Test should occur in 2020.
Archimedes Bioengineering, LLC is a collaborative effort between Children’s National and University of Maryland, College Park (UMCP). Archimedes offers diagnostic solutions to detect metabolic disorders such as Phenylketonuria (PKU) and other such disorders that result from build-up of one or more amino acids in the blood and/or urine. Archimedes hopes to revolutionize the point-of-care market for aminoacidopathy diagnostics.
Mana Therapeutics is bringing powerful cell therapies to bear on cancers with unmet medical need. Focusing on novel ways of educating endogenous immune cells, we have devised cell-based therapies that eliminate cancer cells, with more durable responses, that are safer and have greater breadth than existing therapies.
For more information about Children's National start-ups, please contact:
Director, Office of Innovation and Technology Commercialization
Senior Licensing Associate